Enara Bio has extended and broadened its access to world‐class expertise and capabilities in immuno‐oncology and cell therapy development and manufacturing by appointing new members to its senior leadership team and Scientific Advisory Board (SAB). These appointments will provide experienced industry leadership and perspective to support Enara Bio's rapid growth and development in key strategic areas.
Dr Erik Rutjens as Vice President, Cell Therapy Operations. Dr Rutjens is an expert in cell therapy manufacturing with more than 15 years’ experience in the field and is a PhD‐ trained immunologist.
The company also added two recognized biopharma industry leaders, Dr Sadik Kassim and Dr Michael Quigley, to its SAB to complement its existing academic advisors.
Dr Sadik Kassim, a cell and gene therapy bioprocessing and translational research expert, is currently Chief Technology Officer at Vor Biopharma.
Dr Michael Quigley is currently a Senior Vice President, leading Gilead’s Research Biology Group, overseeing the company's biology teams and preclinical programs, as well as protein biotherapeutics, computational biology and bioinformatics efforts across all therapeutic areas.
Kevin Pojasek, President and CEO of Enara Bio, said: “Enara Bio is growing rapidly, and we need to match our exciting progress with the right expertise. I am extremely pleased to welcome Sadik and Mike to our SAB. Their specialized expertise and strategic input in immuno‐oncology product development will be invaluable in guiding the advancement of our cell therapy platform and pipeline. Erik’s appointment as VP, Cell Therapy Operations also adds essential capabilities to our senior leadership team, as we continue advancing our research and development of next-generation cancer immunotherapies, enabled by our Dark Antigen™ and TCR discovery platforms. I’m thrilled that we’re able to continue to attract top global talent as we grow Enara to a leading player in next‐generation cancer immunotherapy.”
Enara Bio (formerly Ervaxx) is a science-led company targeting the T-cell/cancer-cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. The company is currently a resident at the BioEscalator, but are soon to graduate and move on to The Oxford Science Park.